Bron Kisler Joins Nurocor as SVP Customer Alliances and Partnerships
Globally recognized leader in international standards development joins the leader in digitalized clinical development
Chicago, IL – June 20th, 2022 – Nurocor announced today at DIA Global 2022 that Bron Kisler, co-founder of CDISC, is joining the company as Senior Vice President Customer Alliances and Partnerships. Bron brings more than 20 years of experience, and a vast network of relationships in the pharmaceutical industry to help Nurocor accelerate its mission of digitalized clinical development. Nurocor saves 8 months and $8m in a typical phase 3 trial helping BioPharma companies bring medicines to patients faster.
“I am delighted to join Nurocor as SVP Customer Alliances and Partnerships to help drive adoption of its innovative technology,“ said Bron Kisler. “Nurocor is a visionary company that utilizes digitalized clinical development to reduce clinical trial cycles. It is clear that Nurocor’s solution benefits both pharmaceutical companies and their customers.”
“We are excited to add Bron to our Nurocor team,” said Alex Lazar, president and CEO of Nurocor. “Bron’s expertise and many years’ experience forming innovative partnerships and strategic relationships with BioPharma companies will accelerate Digitalized Clinical Development throughout the pharmaceutical industry.”
Bron Kisler is a luminary in the pharmaceutical industry and a globally recognized leader in international standards development with more than 20 years’ experience. He was co-founder of the Clinical Data Interchange Standards Consortium (CDISC) and CEO of the Clinical Research Data Sharing Alliance (CRDSA). Bron is a member of the International Organization for Standards and was Chair of the Interoperability for Health Informatics Committee, a founding member of the Vienna Vaccine Safety Initiative (ViVI), a member of the US National Cancer Institute (NCI), and is a Biomedical Informatics specialist.
In 2019, Bron was unanimously elected by thirty ISO Member Nations to Chair the newly formed ISO Genomics Sub-Committee and continues to be a thought leader in this endeavor
As co-founder of CDISC, Bron played a pivotal role in CDISC’s growth and international recognition with membership and revenue spanning more than 30 countries. CDISC standards have been widely adopted throughout the world and are required for clinical trials in the US, Japan and soon, China. He was responsible for steering the organization into new clinical and geographic markets, managing strategic partnerships, launching major programs, and identifying growth and development opportunities.
Bron is a founding Member of the Vienna Vaccine Safety Initiative (ViVI) International Scientific Think Tank. ViVI has developed apps to measure and monitor severity and risk for COVID-19 and other respiratory diseases.
As the Interim CEO of the Clinical Research Data Sharing Alliance, Bron spearheads the global priority (set by G7, Health Regulators, & World Health Organization) to drive pharmaceutical sponsors and researchers to share data more widely.
Bron is frequently found sharing his passion for, and knowledge of, clinical standards through speaking engagements at industry conferences. On Wednesday June 22, 2022 Bron is chairing a panel “Democratizing Data for Cancer Research and Real-World Evidence Generation” at DIA Global in Chicago.
For more information about the Nurocor and the Nurocor Clinical Platform please visit us at: https://ncr.brandwithintent.com/.
Nurocor helps BioPharma companies digitalize clinical development to improve the quality of medical research and bring new medicines to patients more quickly. Created by a team combining deep industry expertise with a proven ability to bring technology solutions to market, Nurocor pioneered the Digital Data Flow (DDF) as the heart of BioPharma’s next gen infrastructure. The Nurocor Clinical Platform holistically connects people, process, product, and data with a value-based implementation to automate and optimize the schedule of activities from planning to execution.